Group A* (n = 24) | Group B** (n = 30) | p value | |
---|---|---|---|
Age (median, range) | 61, 42-81 | 59, 24-74 | 0.294 |
Tumor phenotype | |||
ER/PR positive and HER2 negative | 14 | 19 | 0.783 |
HER2 positive | 5 | 5 | 0.695 |
Triple negative | 2 | 6 | 0.277 |
Unknown | 3 | 0 | 0.081 |
Histology | 0.384 | ||
Ductal | 19 | 26 | |
Lobular | 2 | 0 | |
Others | 0 | 1 | |
Unknown | 3 | 3 | |
Initial clinical stage | |||
I | - | 6 | |
II | 7 | 15 | |
III | 8 | 6 | |
IV | 8 | 2 | |
unknown | 1 | 1 | |
Follow-up period (months) | |||
Median (range) | 26 (3–58) | 40.5 (9–69) |